Real-World Dosing Intervals for Long-Acting Anti-VEGF Intravitreal Injection Therapies in nAMD and DME: Academy IRIS ® Registry Analysis

Le résumé fourni par la source

Purpose: To determine real-world dosing intervals for long-acting intravitreal anti–vascular endothelial growth factor (anti-VEGF) therapies in patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Methods: Retrospective observational cohort study in American Academy of Ophthalmology IRIS ® Registry (Intelligent Research in Sight) patients with nAMD or DME treated with aflibercept 8 mg (aflibercept) or faricimab. Mean injection intervals during a ≤24-month period beginning 3 or 4 months after the initial injection were evaluated and descriptively contrasted with those in phase 3 clinical trials. Results: The mean dosing interval was 5–8, 9–12, and ≥13 weeks in 27.5%, 45.6%, and 25.8% of aflibercept-treated patients with nAMD ( n = 40,065); 27.0%, 43.4%, and 28.3% of aflibercept–treated patients with DME ( n = 13,045); 40.5%, 36.1%, and 20.8% of faricimab-treated patients with nAMD ( n = 132,697); and 42.2%, 31.7%, and 22.5% of faricimab-treated patients with DME ( n = 39,849). Dosing intervals were consistent between treatment-naïve and previously treated patients. In aflibercept phase 3 studies, 77% (nAMD) and 89% (DME) of patients achieved a 16-week dosing interval. In faricimab phase 3 studies, 45% (nAMD) and 52% (DME) of patients achieved a 16-week dosing interval. Conclusion: Extension of injection intervals to 16 weeks is greatly reduced in real-world experience compared with phase 3 clinical studies. This discrepancy could be explained by protocol-mandated restrictive rescue criteria used in the registration studies, allowing injection only after vision loss and significant fluid recurrence. Current longer-acting anti-VEGF medications offer an extension to only 5–12 weeks for most patients in the real world.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.